MBB Final Round | Pricing

i

Three standard lenses:

Cost (the floor): unit cost plus a minimum viable margin. Sets the floor below which the client destroys value, but for a consumer product cost-plus alone ignores what drives the price, i.e. willingness to pay.

Competitor / reference: normally you price against rivals. Here there are none. But the closest analogue (a meal-replacement shake) can still anchor a reference, if you add the value of what NuraOne does that the shake does not. It is a starting point, not a price to copy.

Value / willingness to pay (the ceiling): what NuraOne is worth to the customer. One way to decompose this, though not the only one, is money saved on the meal it replaces (small, roughly the same for everyone) plus time saved by not having to eat (worth very different amounts to different people). However it is framed, with no competitor the value to the customer is the ceiling, and because it varies so widely, that ceiling is not a single number.

Conclusion: value will govern, but only after cost and competitor have been checked and shown to set bounds; cost gives a floor, competitor gives a reference range, and value sets the actual price.

Scoring (1 to 4)

4. Explains all three lenses clearly, treats the shake as a reference rather than a price to copy, notes the customer may not be one group, and concludes value governs while cost and competitor only set bounds.
2. Needs prompting to complete the lenses, or defaults to cost-plus / anchors on existing products' prices.
1. Cannot produce the lenses even when prompted, or offers a single method.

Competitor lens: gives a range, not a price. No comparable product, so no price to match. Instead, anchor on the closest analogue (the ~$6 shake) and add the value of what NuraOne does that the shake does not: it removes the eating occasion entirely and keeps you full for twelve hours. Valuing, say, 30 minutes saved at an average hourly rate adds a few dollars, giving a reference around $8 to $15. The key point: that range swings sharply with whose time you value, i.e. a higher hourly value pushes it well past $20, which hints the right price depends on which customer you have in mind.

Cost lens: gives a floor, higher than it looks. Unit cost is $3, but that is not the real floor. Selling one pill at a time direct to consumers adds acquisition, channel, and fulfilment, taking the effective floor for a mass DTC model to around $6.

Conclusion: neither lens pins down a price, and both raise the same question: which customer are we pricing for? The value lens answers it.

Scoring (1 to 4)

4. Builds the competitor reference into a range, notes it swings with whose time is valued, and pushes the cost floor past $3 to the effective DTC floor; concludes neither lens sets a price.
3. Builds a competitor reference range and gets the effective cost floor, but does not notice the time-value sensitivity, or takes $3 at face value.
2. Recognises there is no direct competitor and gives the $3 floor, but does not construct the reference-plus-premium range or probe the effective floor.
1. Treats the shake as a direct competitor to copy, or cannot extract what either lens gives.

Most respondents sit between $5-10, median ~$8, mean ~$10, the mean pulled right by a thin tail paying up to $30, which confirms the Q2 competitor range: for the average consumer, the price is meal-money.

That is a weak result. At $8 the margin looks fine over the $3 unit cost but is thin against the ~$6 DTC floor, leaving NuraOne a low-margin commodity priced just above a $6 shake.

The shape matters more than the median. Mean above median means the sample is not one population: most value the pill at meal-money, a minority at several times that. The people whose time is worth most sit in the tail.

That tail is the real market, not outliers: people who cannot stop to eat during a critical window, i.e. pilots, surgeons, deployed personnel, endurance athletes, long-shift clinical staff. For them the reference is a safety risk or an unfinished task, not an $8 lunch, which is why they sit at $25 to $30. The strategy should flip: lead with this segment, not the mass market, which caps both price and brand.

Scoring (1 to 4)

4. Reads median and mean, sets $8 against the ~$6 floor rather than the $3 cost, reacts to the weak positioning, and reframes the tail as the real market defined by occasion, unprompted.
3. Reads the distribution and reacts to positioning or skew, and identifies the niche, but anchors the margin on the $3 cost, or needs a light prompt to probe the tail.
2. Reads the exhibit and computes a margin but takes $8 as final, needing prompting to see the segment.
1. Misreads the distribution or misses the segment entirely.

Compute contribution per pill, then total annual profit:

Mass-market model ($8):

• Contribution per pill: $8 − $6 = $2.
• Volume: 5,000,000 buyers × 50 pills/year = 250,000,000 pills.
• Annual profit: 250m × $2 = ~$500m.

Niche model ($25):

• Contribution per pill: $25 − $3 = $22.
• Volume: 150,000 buyers × 150 pills/year = 22,500,000 pills.
• Annual profit: 22.5m × $22 = ~$495m.

The two roughly tie (~$500m vs ~$495m). That is the point: the mass market has 33x the buyers, but the niche's 11x higher contribution per pill offsets it. Profit alone does not decide. This is where other considerations need to be made, such as (not exhaustive):

• Mass is a commodity fight. $2 per pill against a $6 floor, launching a new category against an entrenched ~$6 shake. A small conversion slip or competitor response wipes out the profit.
• A niche is defensible and with recurring usage. Predictable usage, no alternative, no competitor to trigger a price war. At 11x the contribution per pill, profit is far less fragile to volume misses.
• A premium brand represents a stronger platform. Launching at $8 fixes NuraOne as a cheap food replacement, capping future pricing; leading with elite occupations builds a serious-performance brand.

Recommendation: price at ~$25 and lead with the niche via institutional subscriptions. Same profit as mass today, better per-unit economics, defensible, brand-building.

Scoring (1 to 4)

4. Computes both models' profit using the differing floors, finds the tie, and picks the niche on strategic grounds (defensibility, resilience, brand).
3. Reaches the tie and picks the niche, but the strategic reasoning is thin or misses the sequencing.
2. Computes the profits but decides mechanically (e.g. picks mass because volume feels bigger, or misses that they tie), or needs prompting to use the correct cost floors.
1. Cannot build the profit comparison or picks a price with no volume reasoning.

Example of a strong one-minute answer:

"My recommendation is to launch NuraOne as a lunch substitute targeting a high-value niche: professions where eating is impossible during a critical window, like pilots, surgeons, deployed personnel and endurance athletes, priced at around $25 a pill through institutional subscriptions. The reason is that for the average consumer NuraOne is only worth about $8, meal-money, a thin premium over an existing shake, whereas this niche values it at $25 to $30 because their alternative is a safety or performance risk, not a cheap lunch. The two models actually make almost the same profit, around $500m each, so the decision isn't about the number, it's that the niche is far more defensible: repeat usage, no price war, 11x times the margin per pill, and it builds a serious-performance brand rather than a commodity one. The main risk is that the niche is small, so I'd prove the value in one flagship occupation first, aviation or surgery, then expand into adjacent ones."

Scoring (1 to 4)

4. Delivers a tight, ~1-minute synthesis as a single story: niche-first recommendation up front, the value split, the profit tie, and the volume risk with a flagship-first next step, without re-walking the case.
3. Covers the recommendation, logic, and risk but runs long or re-explains earlier analysis.
2. Reaches a recommendation but disconnected from the profit tie or segmentation, or hedges back toward mass market.
1. No clear recommendation, or one that ignores the earlier analysis.

Overall: average of the five section scores (1 to 4)